VT News
Steve Perryman

Steve Perryman

Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on the back of its HIV portfolio and new drug launches.
  • Expedia Group reports strong Q2 2025 results, raises full-year guidance amid international gains, sending shares higher.
  • Lilly's oral weight loss pill trails rivals in efficacy, faces market delay due to tolerability concerns.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on the back of its HIV portfolio and new drug launches.
  • Expedia Group reports strong Q2 2025 results, raises full-year guidance amid international gains, sending shares higher.
  • Lilly's oral weight loss pill trails rivals in efficacy, faces market delay due to tolerability concerns.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Steve Perryman

Top Topics

Trending in U.S.

World

Sport